• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Servier makes offer for all shares of Egis Pharmaceuticals

Servier makes offer for all shares of Egis Pharmaceuticals

September 25, 2013
CenterWatch Staff

Servier Group has announced a voluntary public offer (to be made by its wholly-owned subsidiary Arts et Techniques du Progrès) to purchase all outstanding shares in its majority-owned subsidiary Egis Pharmaceuticals for $126 per share in cash.

The offer represents a premium of 33% over the closing price of Egis shares on the Budapest Stock Exchange on Sept. 23, and a premium of 38% over the average trading price of Egis over the six months ended Sept. 23.

Servier Group, a privately-held, research-led pharmaceutical group with global turnover of $5.3 billion in 2012, has owned a majority stake of approximately 51% in Egis since 1995. Servier Group is an innovation-led pharmaceutical group, but also controls three generic pharmaceutical affiliates including Egis, operating in separate markets and each with its own separate management, identity and business strategy.

Egis is a pharmaceutical company in Central and Eastern Europe and the CIS countries, with a portfolio of generic pharmaceuticals. Servier Group does not intend to make any significant changes to the strategy or operations of Egis, which is already well-integrated into Servier Group’s operational structure and will continue to operate under its own identity.

“We remain committed to our strategy of focusing on continued innovative pharmaceutical R&D,” said Dr. Jacques Servier, president and founder of Servier Group. “Egis is the only listed company within Servier Group, but has no need to use the equity capital market for financing, therefore we believe being listed on the Budapest Stock Exchange makes little financial sense for Egis. Our two companies have an 18-year shared history and we know and value highly Egis’ management team and its strategy.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing